John Libbey Eurotext

Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study Volume 22, issue 3, June 2020

Authors
1 Epilepsy Centre, Department of Systems Medicine, University of Rome “Tor Vergata”, Rome,
2 UOC Neurologia, A.O.R.N. “A. Cardarelli”, Naples,
3 Clinica Neurologica, Università “L. Vanvitelli”, Naples,
4 IRCCS Fondazione Santa Lucia, Rome, Italy
* Correspondence: Claudio Liguori Epilepsy Centre, Neurology Unit, Department of Systems Medicine, University of Rome “Tor Vergata”, Viale Oxford 81 - 00133 Rome, Italy

Aim

Perampanel (PER) and brivaracetam (BRV) are third-generation antiseizure medications. The aim of the present retrospective, double-centre study was to compare the effectiveness and tolerability between PER and BRV in adult patients with epilepsy.